Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma [Research Articles]

This study identified two mechanistic subtypes of melanoma: (1) the best responders to clinical BRAF/MEK inhibitors (25%) and (2) nonresponders due to primary resistance mechanisms (9.9%). We identified robust biomarkers that can detect these subtypes in patient samples and predict clinical outcome. TBK1/IKBK inhibitors were selectively toxic to drug-resistant melanoma. Cancer Discov; 7(8); 832–51. ©2017 AACR. See related commentary by Jenkins and Barbie, p. 799. This article is highlighted in the In This Issue feature, p. 783

http://cancerdiscovery.aacrjournals.org/cgi/content/short/7/8/832?rss=1

Source: Cancer Discovery - August 1, 2017 Category: Cancer & Oncology Authors: Eskiocak, B., McMillan, E. A., Mendiratta, S., Kollipara, R. K., Zhang, H., Humphries, C. G., Wang, C., Garcia-Rodriguez, J., Ding, M., Zaman, A., Rosales, T. I., Eskiocak, U., Smith, M. P., Sudderth, J., Komurov, K., Deberardinis, R. J., Wellbrock, C., D Tags: Research Articles Source Type: research